134 related articles for article (PubMed ID: 16972993)
1. Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors.
de Sousa JA; Facina G; da Silva BB; Gebrim LH
Int Semin Surg Oncol; 2006 Sep; 3():29. PubMed ID: 16972993
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of monoclonal antibody MIB-1 in the mammary epithelium adjacent to fibroadenomas in premenopausal women treated with tamoxifen.
de Sousa JA; de Seixas MT; de Lima GR; Baracat EC; Gebrim LH
Breast J; 2001; 7(6):392-7. PubMed ID: 11843850
[TBL] [Abstract][Full Text] [Related]
4. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study.
Rosal MA; da Silva BB
Breast Cancer Res Treat; 2011 Feb; 125(3):797-801. PubMed ID: 21184272
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Detre SI; Ashley S; Mohammed K; Smith IE; Powles TJ; Dowsett M
Cancer Prev Res (Phila); 2017 Mar; 10(3):171-176. PubMed ID: 28100469
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study.
Bajetta E; Celio L; Di Leo A; Bartoli C; Pilotti S; Leutner M; Bono A; Ferrari L; Buzzoni R; Zilembo N; De Candis D; Moglia D
Int J Oncol; 1998 Apr; 12(4):853-8. PubMed ID: 9499446
[TBL] [Abstract][Full Text] [Related]
10. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
11. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen impairs prepubertal mammary development and alters expression of estrogen receptor α (ESR1) and progesterone receptors (PGR).
Tucker HL; Parsons CL; Ellis S; Rhoads ML; Akers RM
Domest Anim Endocrinol; 2016 Jan; 54():95-105. PubMed ID: 26619291
[TBL] [Abstract][Full Text] [Related]
14. [Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients].
Negoiţă M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):834-8. PubMed ID: 22046795
[TBL] [Abstract][Full Text] [Related]
15. The effect of tamoxifen on PCNA expression in fibroadenomas.
Bernardes JR; Seixas MT; Lima GR; Marinho LC; Gebrim LH
Breast J; 2003; 9(4):302-6. PubMed ID: 12846865
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
Decensi A; Robertson C; Viale G; Pigatto F; Johansson H; Kisanga ER; Veronesi P; Torrisi R; Cazzaniga M; Mora S; Sandri MT; Pelosi G; Luini A; Goldhirsch A; Lien EA; Veronesi U
J Natl Cancer Inst; 2003 Jun; 95(11):779-90. PubMed ID: 12783932
[TBL] [Abstract][Full Text] [Related]
17. The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen.
Tregón ML; Blümel JE; Tarín JJ; Cano A
Menopause; 2003; 10(2):154-9. PubMed ID: 12627041
[TBL] [Abstract][Full Text] [Related]
18. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer.
Waseda N; Kato Y; Imura H; Kurata M
Cancer Res; 1981 May; 41(5):1984-8. PubMed ID: 7214366
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast Cancer; 2015 Jan; 22(1):71-8. PubMed ID: 23479208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
